Clinical Trial Update: Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT) [Phase 3]

View source ↗

Summary

Phase 3 trial update on long-term safety of lampalizumab intravitreal injections in geographic atrophy due to age-related macular degeneration; study terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Geographic Atrophy

Drugs mentioned

• lampalizumab (lampalizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Geographic Atrophy | Phase 3 | Status: TERMINATED | Results posted: 2019-02-15